SARS-CoV-2 immune response

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-001202-30-NL

Enrollment

400

Registered

2021-04-16

Start date

2021-05-04

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

immune response to COVDI-19 vaccination

Interventions

Trade Name: COVID-19 vaccin Pfizer COVID-19 vaccin Moderna COVID-19 vaccin AstraZeneca COVID-19 vaccin Janssen Pharmaceutical Form: Injection

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Before and after COVID-19 vaccination Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 200 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 200

Exclusion criteria

Exclusion criteria: < 18 years old

Design outcomes

Primary

Measure	Time frame
Main Objective: immune response after COVID-19 vaccination;Secondary Objective: Not applicable;Primary end point(s): 1 year after final vaccination dose;Timepoint(s) of evaluation of this end point: 1 year after final vaccination dose	—

Secondary

Measure	Time frame
Secondary end point(s): immune response 3 weeks, 3 months and 1 year after final vaccination;Timepoint(s) of evaluation of this end point: immune response 3 weeks, 3 months and 1 year after final vaccination	—

Countries

Netherlands

Contacts

Public ContactHosptial

Diakonessenhuis

sthijsen@diakhuis.nl

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026